Treatment of the polycystic ovary syndrome with lifestyle intervention

Current Opinion in Endocrinology and Diabetes

Volumn 9, Issue 6, 2002, Pages 459-468

  Pasquali, Renato ^a   Gambineri, Alessandra ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; GHRELIN; INSULIN; LEPTIN; LIPID; STEROID 17ALPHA MONOOXYGENASE;

ADRENAL DISEASE; ANOVULATION; BINGE EATING DISORDER; BODY WEIGHT; BULIMIA; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CLINICAL FEATURE; CLINICAL PRACTICE; DIET RESTRICTION; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISTRESS SYNDROME; EATING DISORDER; EXERCISE; FEMALE FERTILITY; HEALTH PROGRAM; HORMONE ACTION; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; HYPOPHYSIS DISEASE; INSULIN RESISTANCE; LIFESTYLE; LOW CALORY DIET; MENSTRUAL CYCLE; METABOLIC DISORDER; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY FUNCTION; OVARY POLYCYSTIC DISEASE; OVULATION; PHENOTYPE; PHYSICAL ACTIVITY; PREGNANCY RATE; QUALITY OF LIFE; REVIEW; STEROIDOGENESIS; TREATMENT PLANNING; WEIGHT REDUCTION;

EID: 0038348574     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-200212000-00004     Document Type: Review

References (87)

1. Zawadszki JK, Dunaif A: Diagnostic criteria for polycystic ovary syndrome. Towards a rational approach. In Polycystic ovary syndrome. Edited by Dunaif A, Haseltine F, Merriam GR. Boston: Blackwell 1992, 377-384.
2. Dunaif A: Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997, 18:774-800.
3. Poretsky L, Cataldo NA, Rosenwaks Z, et al.: The insulin-related ovarian regulatory system in health and disease. Endocr Rev 1999, 20:535-582. This is the most comprehensive review on the role of insulin and the insulin-related system in the pathophysiology of PCOS.
4. Pasquali R, Casimirri F: The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women. Clin Endocrinol (Oxf) 1993, 39:1-16.
5. Gambineri A, Pelusi C, Vicennati V, et al.: Obesity and the polycystic ovary syndrome. Int J Obes 2002, 26: 883-896. This updated review focuses on all pathophysiologic aspects of obesity in PCOS.
6. Cresswell II, Barker DJP, Osmond C, et al.: Fetal growth, length of gestation, and polycystic ovaries in adult life. Lancet 1997, 350:1131-1135.
7. Soule AG: Neuroendocrinology of the polycystic ovary syndrome. Baillieres Clin Endocrinol Metab 1996, 10:205-219.
8. Legro RS: The genetics of obesity: Lessons for polycystic ovary syndrome. Ann NY Acad Sci 2000, 900:193-202. This review focuses on the role of genetic factors in PCOS.
9. Ciaraldi TP, Morales AJ, Hickman MG, et al.: Cellular insulin resistance in adipocytes from obese polycystic ovary syndrome subjects involves adenosine modulation of insulin sensitivity. J Clin Endocrinol Metab 1997, 82:1421-1425.
10. Morales AJ, Laughlin GA, Båtzow T, et al.: Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab 1996, 81:2854-2864.
11. Holte J, Bergh T, Gennarelli G, et al.: The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women. Clin Endocrinol (Oxf) 1994, 41:473-481.
12. Conway GS, Agrawal R, Betteridge DJ, et al.: Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992, 37:119-125.
13. Dunaif A, Finegood DT: β-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996, 81:942-947.
14. Morin-Papunen LC, Vauhkonen I, Koivunen RM, et al.: Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Hum Reprod 2000, 15:1266-1274.
15. Grulet H, Heeart AC, Delemer B, et al.: Roles of LH and insulin resistance in lean and obese polycystic ovary syndrome. Clin Endocrinol (Oxf) 1993, 38:621-626.
16. Harris MI, Hadden WC, Knowler WC: Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in the US population aged 20-74. Diabetes 1987, 36:523-534.
17. Vettor R, Lombardi AM, Fabris R, et al.: Substrate competition and insulin action in animal models. Int J Obes 2000, 24: S22-S24.
18. Ehrmann DA, Sturis J, Byrne MM, et al.: Insulin secretory defects in polycystic ovary syndrome, relation to insulin sensitivity and family history of non insulin diabetes mellitus. J Clin Invest 1995, 96:520-527.
19. Mahabeer S, Naidoo C, Norman RJ, et al.: Metabolic profiles and lipoprotein lipid concentrations in nonobese and obese patients with polycystic ovary syndrome. Horm Metab Res 1990, 22:537-540.
20. Hartz AJ, Barboriak PN, Wong A, et al.: The association of obesity with infertility and related menstrual abnormalities in women. Int J Obes 1979, 3:57-77.
21. Kiddy DS, Sharp PS, White DM, et al.: Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin Endocrinol (Oxf) 1990, 32:213-220.
22. Pasquali R, Casimirri F, Cantobelli S, et al.: Insulin and androgen relationships with abdominal body fat distribution in women with and without hyperandrogenism. Horm Res 1993, 39:179-187.
23. Pasquali R, Casimirri F, Venturoli S, et al.: Body fat distribution has weight-independent effects on clinical, hormonal and metabolic features of women with polycystic ovary syndrome. Metabolism1994, 43:706-713.
24. Bjorntorp P: The regulation of adipose tissue distribution in humans. Int J Obes 1996, 20:291-302.
25. Zamorano PL, Mahesh VB, De Sevilla LM, et al.: Expression and localization of the leptin receptor in endocrine and neuroendocrine tissues of the rat. Neuroendocrinology 1997, 65:223-228.
26. Tena-Sempere M, Barreio ML, Gonzalez LC, et al.: Novel expression and functional role of ghrelin in rat testis. Endocrinology 2002, 143:717-725. This study provides fundamental data on the role of ghrelin in the regulation of gonadal steroidogenesis.
27. (Pagotto U, Gambineri A, Vicennati V, Heiman ML, Tschoep M, and Pasquali R. Ghrelin, obesity and the polycystic ovary syndrome: correlations with insulin resistance and androgen levels. J Clin Endocrinol Metab, in press.
28. Pasquali R, Vicennati V: Activity of the hypothalamic-pituitary-adrenal axis in different obesity phenotypes. Int J Obes 2000, 24: S47-S49.
29. Holmäng A, Larsson BM, Brzezcinska Z, et al.: Effects of short-term testosterone exposure on insulin sensitivity of muscles in female rats. Am J Physiol 1992, 262:E851-855.
30. Björntorp P: Metabolic implications of body fat distribution. Diabetes Care 1991, 14:1132-1143.
31. White DM, Polson DW, Kiddy D, et al.: Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. J Clin Endocrinol Metab 1996, 81:3821-3824.
32. Galtier-Dereure F, Pujol P, Dewailly D, et al.: Choice of stimulation in polycystic ovarian syndrome: the influence of obesity. Human Reprod 1997, 12:88-96.
33. Lobo RA, Gysler M, March CM, et al.: Clinical and laboratory predictors of clomiphene response. Fertil Steril 1982, 37:168-174.
34. Fedorcsák P, Dale PO, Storeng R, et al.: The impact of obesity and insulin resistance on the outcome of IVF or ICSI in women with polycystic ovarian syndrome. Hum Reprod 2001, 16:1086-1091.
35. Fedorsak P, Storeng R, Dale PO, et al.: Obesity is a risk factor for early pregnancy loss after IVF or ICSI. Acta Obstet Gynecol Scand 2000, 79:43-48.
36. Morin-Papuonen LC, Koivunen RM, Ruokonen A, et al.: Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 1998, 69:691-696.
37. Velazquez EM, Mendoza S, Hamer T, et al.: Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994, 43:647-654.
38. Dunaif A, Scott D, Finegood D, et al.: The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996, 81:3299-3306.
39. Nestler JE, Jakubowicz DJ, Evans WS, et al.: Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;25:1876-1880.
40. Pirke KM, Schweiger U, Laessle R, et al.: Dieting influences the menstrual cycle: vegetarian versus non-vegetarian diet. Fertil Steril 1986, 46:1083-1088.
41. Snow RC, Schneider JL, and Barbieri RL: High dietary fiber and low saturated fat intake among oligomenorrheic undergraduates. Fertil Steril 1990, 54:632-637.
42. Rose DP, Goldman M, Connolly JM, et al.: High fiber diet reduces serum estrogen concentrations in premenopausal women. Am J Clin Nutr 1991, 54:520-525.
43. Longcope C, Feldman HA, McKinlay JB, et al.: Diet and sex hormone-binding globulin. J Clin Endocrinol Metab 2000, 85:293-296.
44. Jenkins DJ, Jenkins AL: Dietary fiber and the glycemic response. Proc Soc Exp Biol Med 1985, 80:422-431.
45. Fukagawa NK, Anderson JW, Hageman G, et al.: High-carbohydrate, high-fiber diets increase peripheral insulin sensitivity in healthy young and old adults. Am J Clin Nutr 1990, 52:524-528.
46. Stevens J: Does dietary fiber affect food intake and body weight? J Am Diet Assoc 1988, 88:939-942.
47. Abbasi F, McLaughlin T, Lamendola C, et al.: High carbohydrate diets, triglyceride-rich lipoproteins, and coronary heart disease risk. Am J Cardiol 2000, 85:45-48.
48. Spiller GA, Jensen CD, Pattisoon TS, et al.: Effect of protein dose on serum glucose and insulin response to sugars. Am J Clin Nutr 1987, 44:847-856.
49. Thissen JP, Ketelslegers JM and Underwood LE: Nutitional regulation of the insulin like growth factors. Endocr Rev 1994, 15:80-101.
50. Trowell H, Burkitt D, Heaton K: Dietary Fiber, Fiber-Depleted Foods and Disease. Academic Press, London, 1985.
51. Lissner L, Levitsky DA, Strupp BJ, et al.: Dietary fat and the regulation of energy intake in human subjects. Am J Clin Nutr 1987, 46:886-892.
52. World Health Organization: Factors influencing the development of overweight and obesity. In: Obesity: preventing and managing the global epidemic. Report of a WHO Consultation on Obesity. Geneva, 3-5 June 1997.
53. Wild RA, Painter PC, Coulson RB, et al.: Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1985, 61:946-951.
54. McCluskey S, Evans C, Lacey JH, et al.: Polycystic ovary syndrome and bulimia. Fertil Steril 1991, 55:287-291. This unique study demonstrates an association between eating disorders and PCOS.
55. Crisp AH, Ellis J, Lowy C: Insulin response to a rapid intravenous injection of dextrose in patients with anorexia nervosa and obesity. Postgrad Med J 1967, 43:97.
56. Schweiger U, Poellinger J, Laessle R, et al.: Altered insulin response to a balanced test meal in bulimic patients. Int J Eating Disord 1987, 6:551.
57. Sonino N, Fava GA, Mani E, et al.: Quality of life of hirsute women. Postgrad Med J 1993, 69:186-189.
58. Cronin L, Guyatt G, Griffith L, et al.: Development of a Health-Related Quality-of-Life Questionnaire (PCOSQ) for Women with Polycystic Ovary Syndrome (PCOS). J Clin Endocrinol Metab 1998, 83:1976-1987. This study validated a quality-of-life questionnaire in PCOS.
59. Segal KR, Dunaif A: Resting metabolic rate and postprandial thermogenesis in polycystic ovary syndrome. Int J Obes 1990, 14:559-567.
60. Jaatinen T-A, Anttila L, Erkkola R, et al.: Hormonal responses to physical exercise in patients with polycystic ovarian syndrome. Fertil Steril 1993, 60:262-267.
61. Richter EA, Mikines KJ, Galbo H, et al.: Effect of exercise on insulin action in human skeletal muscle. J Appl Physiol 1989, 66:876-885.
62. Mikines KJ, Sonne B, Farrell PA, et al.: Effect of physical exercise on sensitivity and responsiveness to insulin in humans. Am J Physiol 1988, 254:248-259.
63. Marshall K: Polycystic ovary syndrome: clinical considerations. Altern Med Rev 2001,6:272-292.
64. Van Hooff MH, Voorhorst FJ, Kaptein MB, et al.: Polycystic ovaries in adolescents and the relation with menstrual cycle patterns, luteinizing hormone, androgens, and insulin. Fertil Steril 2000, 74:49-58.
65. Harlass FE, Plymate SR, Fariss BL, et al.: Weight loss is associated with correction of gonadotropin and sex steroid abnormalities in the obese anovulatory female. Fertil Steril 1984, 42:649-652.
66. Pasquali R, Antenucci D, Casimirri F, et al.: Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 1989, 68:173-179.
67. Kiddy DS, Hamilton-Fairley D, Bush A, et al.: Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992, 36:105-111.
68. Guzick DS, Wing R, Smith D, et al.: Endocrine consequences of weight loss in obese, hyperandrogenic anovulatory women. Fertil Steril 1994, 61:598-604.
69. Hamilton-Fairley D, Kiddy D, Anyaoku A, et al.: Response of sex hormone binding globulin and insulin-like growth factor binding protein-1 to an oral glucose tolerance test in obese women with polycystic ovary syndrome before and after calorie restriction. Clin Endocrinol (Oxf) 1993, 39:363-367.
70. Holte J, Bergh T, Berne C, et al.: Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome J Clin Endocrinol Metab 1995, 80:2586-2593.
71. Andersen P, Seljeflot I, Abdelnoor M, et al.: Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism 1995, 44:611-616.
72. Jakubowicz DA, Nestler JE: 17α-Hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome after weight loss. J Clin Endocrinol Metab 1997, 82:556-560. This study demonstrats that low-calorie diet may improve the activity of the P450c17α in PCOS.
73. Vahrenberg H, Ek I, Reynisdottir S, et al.: Divergent effects of weight reduction and oral anticonception treatment on adrenergic lipolysis regulation in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1999, 84:2182-2187.
74. Huber-Buchholz MM, Carey DGP, Norman RJ: Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: Role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999, 84:1470-1474.
75. Pasquali R, Gambineri A, Biscotti D, et al.: Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen, and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000, 85:2767-2774. In this controlloed study metformin added to low-calorie diet proved to be more effective than placebo in reducing insulin and androgen levels and visceral fat tissue.
76. Hollmann M, Runnebaum B, Gerhard I: Effects of weight loss on the hormonal profile in obese, infertile women. Hum Reprod 1996, 11:1884-1891.
77. Clark AM, Ledger W, Galletly C, et al.: Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 1995, 10:2705-2712.
78. Dunaif A, Scott D, Finegood D, et al.: The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996, 81:3299-3306.
79. Ehrmann DA: Insulin-lowering therapeutic modalities for polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999, 28:423-438.
80. Kim LH, Taylor AE, Barbieri RL: Insulin sensitizers and polycystic ovary syndrome: Can a diabetes medication treat infertility? Fertil Steril 2000, 73:1097-1098. This review emphasizes the role of insulin sensitizers in the treatment PCOS-related infertility.
81. Mitwally MF, Kuscu NK, Yalcinkaya TM: High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome. Hum Reprod 1999, 14;2700-2703.
82. Moghetti P, Castello R, Negri C, et al.: Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: A randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000, 85:139-146.
83. Morin-Papunen LC, Koivunen RM, Ruokonen A, et al.: Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 1998, 69:691-696.
84. Velazquez EM, Mendoza S, Hamer T, et al.: Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994, 43:647-654.
85. Imani B, Eijkemans MJ, te Velde ER, et al.: Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligomenorrheic infertility. J Clin Endocrinol Metab 1998, 83;2361-2365.
86. Shepard MK, Balmaceda JP, Leija CG: Relation of weight to successful induction of ovulation with clomiphene citrate. Fertil Steril 1979, 32:641-645.
87. Franks S, Hamilton-Fairley D: Ovulation induction: Gonadotropins. In Reproductive Endocrinology, Surgery, and Technology, vol 2. Edited by Adashi EY, Rock JA, Rosenwaks Z. Philadelphia: Lippincott-Raven; 1996:1207-1223.